<DOC>
	<DOCNO>NCT01449058</DOCNO>
	<brief_summary>This multi-center , open-label , dose-finding , phase Ib study estimate maximum tolerate dose ( ) ( MTD ( ) ) and/or recommend dose ( ) expansion ( RDE ( ) ) orally administer combination BYL719 MEK162 . This combination explore adult patient advance CRC , esophageal cancer , pancreatic cancer , NSCLC , ovarian cancer , advance solid tumor adult patient AML high risk high risk MDS , document RAS BRAF mutation . Dose escalation guide Bayesian logistic regression model overdose control . At MTD RDE , four expansion arm open order ass safety preliminary activity combination BYL719 MEK162 specific patient population .</brief_summary>
	<brief_title>A Phase Ib Study MEK162 Plus BYL719 Adult Patients With Selected Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically/cytologically confirm , advance solid tumor , AML high risk high risk MDS Measurable disease determine RECIST 1.1 Primary CNS tumor CNS tumor involvement Diabetes mellitus Unacceptable ocular/retinal condition Clinically significant cardiac disease impair cardiac function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced solid tumor ,</keyword>
	<keyword>AML</keyword>
	<keyword>high risk high risk MDS</keyword>
	<keyword>dose escalation ,</keyword>
	<keyword>RAS/BRAF mutation ,</keyword>
	<keyword>PI3K inhibitor ,</keyword>
	<keyword>MEK inhibitor ,</keyword>
	<keyword>BYL719 ,</keyword>
	<keyword>MEK162</keyword>
</DOC>